Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Asthma–chronic obstructive pulmonary disease (COPD ... trials to evaluate specific drug interventions on important outcomes such as lung function, acute exacerbations, quality of life and ...

Centre, a national research platform led by Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...

The drug provides both bronchodilation ... could also be heading for approval in COPD – at the second attempt – after reducing exacerbations in the phase 3 MATINEE trial, while Amgen and ...

Sinead O'Connor's cause of death has been revealed, as well as the contents of her will, in which she asked her children to 'milk' her music to boost sales ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Emphysema is a chronic lung condition that affects millions of people worldwide and can make everyday activities such as ...

[8] The analysis concluded that these drugs, taken long term, could be most useful in patients who have repeated, prolonged or severe exacerbations of COPD. Hence, in some European and extra ...

The programme – spearheaded by The Academic Respiratory Initiative for Pulmonary Health (Tariph) Centre under LKCMedicine – ...